- Home
- CRT vs ONCY Comparison
CRT vs ONCY Comparison
Compare CRT & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- ONCY
- Stock Information
- Founded
- CRT 1991
- ONCY 1998
- Country
- CRT United States
- ONCY Canada
- Employees
- CRT N/A
- ONCY N/A
- Industry
- CRT Oil & Gas Production
- ONCY Pharmaceuticals and Biotechnology
- Sector
- CRT Energy
- ONCY Health Care
- Exchange
- CRT Nasdaq
- ONCY Nasdaq
- Market Cap
- CRT 65.1M
- ONCY 49.1M
- IPO Year
- CRT 1992
- ONCY 1999
- Fundamental
- Price
- CRT $9.70
- ONCY $0.91
- Analyst Decision
- CRT
- ONCY Strong Buy
- Analyst Count
- CRT 0
- ONCY 4
- Target Price
- CRT N/A
- ONCY $4.33
- AVG Volume (30 Days)
- CRT 22.2K
- ONCY 1.4M
- Earning Date
- CRT 01-01-0001
- ONCY 07-31-2025
- Dividend Yield
- CRT 9.19%
- ONCY N/A
- EPS Growth
- CRT N/A
- ONCY N/A
- EPS
- CRT 0.99
- ONCY N/A
- Revenue
- CRT $6,834,116.00
- ONCY N/A
- Revenue This Year
- CRT N/A
- ONCY N/A
- Revenue Next Year
- CRT N/A
- ONCY N/A
- P/E Ratio
- CRT $9.75
- ONCY N/A
- Revenue Growth
- CRT N/A
- ONCY N/A
- 52 Week Low
- CRT $8.88
- ONCY $0.33
- 52 Week High
- CRT $13.31
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- CRT 41.50
- ONCY 78.49
- Support Level
- CRT $9.74
- ONCY $0.71
- Resistance Level
- CRT $9.99
- ONCY $0.81
- Average True Range (ATR)
- CRT 0.18
- ONCY 0.09
- MACD
- CRT 0.00
- ONCY 0.02
- Stochastic Oscillator
- CRT 8.11
- ONCY 90.48
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.